Allergic rhinitis (AR) is prevalent in Singapore, with a significant disease burden. Afflicting
up to 13% of the population, AR impairs quality of life, leads to reduced work productivity
and is an independent risk factor for asthma. In the last 2 decades, local studies have
identified patient and physician behaviours leading to suboptimal control of the disease. Yet,
there is an overall lack of attention to address this important health issue. Allergic Rhinitis
and its Impact on Asthma (ARIA) is a European organisation aimed at implementing
evidence-based management for AR worldwide. Recent focus in Europe has been directed
towards empowering patients for self-management, exploring the complementary role of
mobile health, and establishing healthcare system-based integrated care pathways.
Consolidation of these ongoing efforts has led to the release of the 2019 ARIA care
pathways. This review summarises the ARIA update with particular emphasis on the
current status of adult AR in Singapore. In addition, we identify unmet needs and future
opportunities for research and clinical care of AR in the local context.
Keywords: Allergen immunotherapy, Allergic Rhinitis and its Impact on Asthma,
clinical guideline